2 Outstanding Dividend Stocks That Are Too Cheap to Ignore

The article identifies Zoetis (ZTS) and Nomad Foods (NOMD) as deeply undervalued dividend stocks, both trading at historically low valuations despite their leadership positions in animal healthcare and European frozen foods, respectively. Zoetis has seen its stock decline due to post-pandemic normalization and initial underperformance of new drugs, but maintains robust innovation and profitability, offering a 1.7% dividend yield. Nomad Foods, trading at its lowest-ever EV/EBITDA multiple after a weather-impacted quarter, is actively repurchasing shares and offers a 5.7% dividend yield, with both companies presented as compelling 'buy-the-dip' opportunities for dividend-focused investors.

Analysis

Zoetis (ZTS) and Nomad Foods (NOMD) are presented as significantly undervalued dividend stocks, trading at once-in-a-decade low valuations despite their respective market leadership positions. This valuation chasm is attributed to a broader market divergence favoring high-volatility growth stocks, leaving low-beta dividend stocks like ZTS and NOMD attractively priced.

Zoetis, the global leader in animal healthcare, currently trades at its lowest-ever 20 times earnings multiple, with an all-time high 1.7% dividend yield. While the company faced challenges from post-pandemic normalization and initial underperformance of new monoclonal antibody drugs, its robust innovation engine, evidenced by upcoming longer-lasting mAb versions, and elite 22% return on invested capital (ROIC) underscore fundamental strength.

Nomad Foods, Europe's leading frozen foods provider, has seen its stock plummet 62% from its 2021 high, now trading at its lowest-ever enterprise value to EBITDA multiple of 7. Despite a recent 2% sales and 11% adjusted earnings decline due to industry-wide weather disruptions, management projects 15% annual free cash flow growth through 2028 and is aggressively repurchasing shares, complemented by a new 5.7% dividend yield and significant insider buying.

Key Decisions for Investors

• Investors should consider Zoetis (ZTS) as a "buy-the-dip" candidate, given its historically low valuation, robust innovation pipeline, and strong capital returns, while monitoring the market reception of its next-generation osteoarthritis treatments.
• Nomad Foods (NOMD) presents a deeply discounted value opportunity, supported by its market leadership, aggressive share repurchases, and significant insider buying, despite recent weather-impacted sales.
• Evaluate both companies' long-term growth trajectories and dividend sustainability in the context of their current attractive valuations and management's shareholder-friendly capital allocation strategies.